The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in Δ F508-Homozygous Cystic Fibrosis Patients: Partial Restoration of Nasal Epithelial CFTR Function
Abstract
Sodium 4-phenylbutyrate (Buphenyl, 4PBA) is a new FDA approved drug for management of urea cycle disorders. We have previously presented data suggesting that 4PBA, at clinically achievable concentrations, induces CFTR channel function on the plasma membrane of deltaF508-expressing cystic fibrosis (CF) airway epithelial cells in vitro (Rubenstein, R. C., and P. L. Zeitlin, 1997. J. Clin. Invest. 100:2457-2463). We hypothesized that 4PBA would induce epithelial CFTR function in vivo in individuals homozygous for deltaF508-CFTR. A randomized, double-blind, placebo-controlled trial in 18 deltaF508-homozygous patients with CF was performed with the maximum approved adult dose of 4PBA, 19 grams p.o. divided t.i.d., given for 1 wk. Nasal potential difference (NPD) response patterns and sweat chloride concentrations were determined before and after study drug treatment, and 4PBA and metabolites were assayed in plasma and urine at the end of study drug treatment. Subjects in the 4PBA group demonstrated small, but statistically significant improvements of the NPD response to perfusion of an isoproterenol/amiloride/chloride-free solution; this measure reflects epithelial CFTR function and is highly discriminatory between patients with and without CF. Subjects who had received 4PBA did not demonstrate significantly reduced sweat chloride concentrations or alterations in the amiloride-sensitive NPD. Side effects due to drug therapy were minimal and comparable in the two groups. These data are consistent with 4PBA therapy inducing CFTR function in the nasal epithelia of deltaF508-homozygous CF patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Degradation of CFTR by the ubiquitin-proteasome pathway
Ward, C. L., Omura, S., & Kopito, R. R. (1995) · Cell · doi:10.1016/0092-8674(95)90240-6 · Cited by 1,304
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,234
Multiple proteolytic systems, including the proteasome, contribute to CFTR processing
Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., & Riordan, J. R. (1995) · Cell · doi:10.1016/0092-8674(95)90241-4 · Cited by 897
Chloride impermeability in cystic fibrosis
Quinton, P. M. (1983) · Nature · doi:10.1038/301421a0 · Cited by 767
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation
Sato, S., Ward, C. L., Krouse, M. E., Wine, J. J., & Kopito, R. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.635 · Cited by 519
Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties
Sheppard, D. N., Rich, D. P., Ostedgaard, L. S., Gregory, R. J., Smith, A. E., & Welsh, M. J. (1993) · Nature · doi:10.1038/362160a0 · Cited by 467
A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders
Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S.-P., Vichinsky, E. P., & Olivieri, N. F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280202 · Cited by 437
Brown, C. R., Hong-Brown, L. Q., Biwersi, J., Verkman, A. S., & Welch, W. J. (1996) · Cell Stress & Chaperones · doi:10.1379/1466-1268(1996)001<0117:ccctmp>2.3.co;2 · Cited by 417
Rubenstein, R. C., Egan, M. E., & Zeitlin, P. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119788 · Cited by 389
Self-citationKnowles, M. R., Paradiso, A. M., & Boucher, R. C. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.4-445 · Cited by 308
Zabner, J., Ramsey, B. W., Meeker, D. P., Aitken, M. L., Balfour, R. P., Gibson, R. L., Launspach, J., Moscicki, R. A., Richards, S. M., & Standaert, T. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118573 · Cited by 265
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial
Collins, A., Pearson, H., Giardina, P., McDonagh, K., Brusilow, S., & Dover, G. (1995) · Blood · doi:10.1182/blood.v85.1.43.bloodjournal85143 · Cited by 261
The cystic fibrosis mutation (ΔF508) does not influence the chloride channel activity of CFTR
Li, C., Ramjeesingh, M., Reyes, E., Jensen, T., Chang, X., Rommens, J. M., & Bear, C. E. (1993) · Nature Genetics · doi:10.1038/ng0493-311 · Cited by 191
Zabner, J., Cheng, S. H., Meeker, D., Launspach, J., Balfour, R., Perricone, M. A., Morris, J. E., Marshall, J., Fasbender, A., Smith, A. E., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119676 · Cited by 176
Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion
Brusilow, S. W. (1991) · Pediatric Research · doi:10.1203/00006450-199102000-00009 · Cited by 169
Extended Therapy with Intravenous Arginine Butyrate in Patients with β-Hemoglobinopathies
Sher, G. D., Ginder, G. D., Little, J., Yang, S., Dover, G. J., & Olivieri, N. F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322404 · Cited by 168
Pasyk, E. A., & Foskett, J. K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12347 · Cited by 167
McCance, R. A. (1938) · The Journal of Physiology · doi:10.1113/jphysiol.1938.sp003595 · Cited by 106
Kelley, T. J., Thomas, K. R., Milgram, L. J. H., & Drumm, M. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2604 · Cited by 96
Perrine, S. P., Olivieri, N. F., Faller, D. V., Vichinsky, E. P., Dover, G., & Ginder, G. D. (1994) · PubMed · Cited by 56
Kelley, T. J., Al‐Nakkash, L., Cotton, C. U., & Drumm, M. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118819 · Cited by 56
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Ratjen, F., & Döring, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12567-6 · Cited by 885
Medical and Ethical Consequences of the Human Genome Project
Collins, F. S. (1991) · The Journal of Clinical Ethics · doi:10.1086/jce199102411 · Cited by 666
Medical and Societal Consequences of the Human Genome Project
Collins, F. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410106 · Cited by 578
Metadata
- Authors
- RUBENSTEIN, R. C., & ZEITLIN, P. L.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-02-01
- Volume
- 157
- Issue
- 2
- Pages
- 484-490
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2132775040
- Cited by
- 340
- References
- 23
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.